The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study

• Published in: International Journal of Circumpolar Health
• Main Authors: Alvarez, G. G., Van Dyk, D., Mallick, R., Lesperance, S., Demaio, P., Finn, S., Potvin, S. Edmunds, Patterson, M., Pease, C., Amaratunga, K., Hui, C., Cameron, D.W., Mulpuru, S., Aaron, S.D., Momoli, F., Zwerling, A.
• Format: Text
• Language: English
• Published: Taylor & Francis 2020
• Subjects: Original Research Article; Arctic; Canada; Nunavut; Qikiqtarjuaq; Circumpolar Health; inuit; Iqaluit
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241515/; http://www.ncbi.nlm.nih.gov/pubmed/32379538; https://doi.org/10.1080/22423982.2020.1758501

Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational post...